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Busulfan, a bifunctional alkylating agent with potent
toxicity for hematopoietic cells (and sinusoidal endothelial
cells), was originally introduced in 1952 for patients with
chronic myelogenous leukemia (CML) [1]. In 1975, bone
marrow transplantation (BMT) researchers at Johns Hop-
kins University chose it as a substitute for total body irradia-
tion in a bone marrow ablative regimen [2]. Until recently,
busulfan remained one of very few cytotoxic drugs that
oncologists use in oral formulations and the only therapeu-
tic agent aside from hormonal therapy that was available
exclusively in tablet form. 
Oral busulfan administration is often complicated by eme-
sis requiring erratic replacement of vomited tablets, seizures,
mucositis, and a relatively unique adverse effect, hepatic veno-
occlusive disease (HVOD), also called sinusoidal obstruction
syndrome (reviewed in [3]). Evaluation of the role of thera-
peutic drug monitoring (TDM) of busulfan was undertaken
because of the large variability in apparent clearance rates (and
therefore drug exposure) expected of an orally administered
and hepatically cleared agent and the frequency of a relatively
unique toxicity that contributed substantially to regimen-
related mortality [4,5]. In addition to the problem of oral dos-
ing producing high portal venous exposures, TDM of busul-
fan, an oral agent with a short half-life, is complicated for
more than 10% of patients because delayed absorption and
emesis result in difﬁculty estimating an area under the curve
(AUC), even with relatively complete sampling schedules. 
Development of agents for BMT preparative regimens
has generally not been undertaken with support for large,
well-controlled studies from large pharmaceutical compa-
nies and stringent FDA review. Many investigators have
performed small studies rather than forging large collabora-
tions to produce definitive evidence-based recommenda-
tions. For busulfan, an extremely insoluble agent, parenteral
formulations were ﬁrst attempted in the last decade, includ-
ing formulations in dimethyl sulfoxide [6]; N,N-dimethylac-
etamide (DMA) and polyethylene glycol 400 (PEG400)
(Busulfex; Orphan Medical, Minnetonka, MN) [7]; lipo-
somes [8]; and microcrystalline lipids (Spartaject busulfan;
SuperGen, Dublin, CA) [9]. Four articles in the current
issue of Biology of Blood and Marrow Transplantation [10-13]
discuss the clinical and pharmacologic experience using
Busulfex in preparative regimens with 2 doses of cyclophos-
phamide or 5 days of ﬂudarabine.
Russell et al. [10] have commendably published a clini-
cal series of 70 patients treated concurrently with busulfan
and ﬂudarabine. Projected disease-free survival at 2 years is
73% for their “low risk” patients, 32% for advanced acute
myelogenous leukemia, and 65% for other “high-risk”
patients. Unfortunately, rather than use a minimal sampling
scheme to establish busulfan exposure levels for all the
patients, they performed detailed pharmacokinetic evalua-
tion for a subset of only 12 patients. Although none of the
patients met clinical criteria for VOD, 62 of 70 patients had
transient bilirubin elevations, suggesting that the higher
peak concentrations occurring with a 3-hour infusion of
3.2 mg/kg were tolerated. Neither of the 2 patients with
graft failure had pharmacokinetic evaluation, and it will not
be possible to analyze a relationship between outcomes and
drug exposure. 
Andersson et al. [11] report on the pharmacokinetics
and clinical outcomes of 36 patients with CML treated
with intravenous (IV) busulfan and cyclophosphamide
(BuCy2). As noted for the Russell et al. busulfan/fludara-
bine study, none of the patients in the Andersson et al.
study met criteria for VOD, but 10 patients did develop
grade 2 to 3 elevations in bilirubin. Engraftment occurred
in all of these patients. Eleven deaths were due to chronic
graft-versus-host disease (cGVHD) or recurrent disease.
Despite the absence of acute life-threatening regimen-
related toxicity in these study patients, these investigators
chose to dose-adjust the BuCy2 regimens of the final
11 patients in their series to achieve an AUC between
950 and 1520 µmol*min, consistent with prior recommen-
dations for oral doses. As expected, more toxicity was
identified in patients with higher busulfan AUC values.
However, the investigators also noted an increase in late
mortality associated with both inadequate and excessive
exposure. This outcome may be interpreted to mean either
(1) that patients with altered busulfan clearance have
underlying conditions that increase their likelihood of suc-
cumbing to late complications or (2) that inadequate or
excessive busulfan exposure is directly causative of the poor
outcomes. It is not easy to surmise an etiologic relation-
ship, eg, between inadequate exposure to busulfan and
increased likelihood of death from cGVHD. Thus,
although the relationship between median exposure and
better outcome in this study was consistent with that
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reported for prior studies [4,14], the standard of proof for
“evidence-based medicine” for TDM and dose adjustment
is not at the high level that a randomized trial of “one dose
fits all” versus “individualized dosing” would provide.
Fernandez et al. [12] also explored twice daily and daily
(QD) schedules that can increase the convenience of admin-
istering the preparative BuCy2 regimen to facilitate outpa-
tient treatment. Linear pharmacokinetics have been seen
with oral doses of 4 mg/kg QD in adults (personal commu-
nication) and children [15], with similar tolerability to that
in this small series of 12 patients treated with IV busulfan.
Despite relatively high overall exposures during the 4 days
of treatment, in part because doses were based on actual
body weight, only 1 patient had HVOD, and only 1 patient
died of acute regimen-related toxicity. The investigators also
employed an extended infusion schedule, partly to mimic
the known safety profile of the concentration-versus-time
exposure curves produced by oral doses. For an every-
6-hour schedule, a 90-minute infusion will closely mimic
the systemic concentrations produced by an oral dose in a
“typical” patient while producing much lower portal vein
concentrations. For once-daily dosing, the 4-hour infusion
used by Fernandez et al. [12] produced concentrations simi-
lar to those in the 12 patients studied by Russell et al. [10]
(with a 3-hour infusion),with systemic peak concentrations
that were only 2-to-3–fold higher than those reached after
oral doses of 1 mg/kg. Based on the relatively slow alkyla-
tion rate for this agent, the larger differences between peak
and trough concentrations produced by once-daily dosing
are unlikely to be critical to either toxicity or efﬁcacy.
Finally, Kashyap et al. [13] compared the rate of HVOD
occurring in 10 (33%) of 30 patients treated with oral BuCy2
(with 6 HVOD-related deaths) and 5 (8%) of 61 patients
treated with IV BuCy2 (with 2 HVOD-related deaths), pro-
viding additional reassurance that IV busulfan is relatively
well tolerated. 
Parenteral busulfan formulations can reduce hepatic
sinusoidal exposure and reduce but not eliminate the inter-
patient variability in systemic exposure, as well as eliminat-
ing the dosing uncertainties associated with emesis. The
2-fold range of AUC after administration of IV busulfan
preparations is as narrow a range as would be achievable
with oral dosing of busulfan with therapeutic monitoring.
However, hepatic injury continues to be evident, with
Kashyap et al. [13] reporting 6 of 10 patients with VOD
dying in the series of oral busulfan patients, and 2 of
5 patients with VOD dying after parenteral busulfan. Fur-
thermore, these small series present what may be a typical
incidence of pulmonary complications, but it is not possible
to determine deﬁnitively in the Fernandez et al. [12] series
of 12 patients that the patient who died on day +21 of pre-
sumed fungal pneumonia did not have pulmonary damage
from parenteral busulfan.
None of these trials took advantage of the potential for
simpliﬁed therapeutic monitoring when busulfan is given IV.
When busulfan is given by mouth, extensive sampling is
required to deﬁne the AUC because there are unpredictable
periods of dissolution, absorption, and elimination. A mini-
mal sampling schedule with 3 to 4 samples after a test oral
dose has been successfully used with Bayesian priors to pre-
dict the AUC and reduce the incidence of VOD [16]. With
parenteral delivery, only 2 samples may be needed to reli-
ably predict the AUC after an IV test dose. Therapeutic
drug monitoring, used routinely for drugs that have a much
less serious toxicity proﬁle, might further reduce the inci-
dence of VOD (and particularly, lethal VOD). A test dose,
followed by once-daily IV dosing, may both simplify treat-
ment and reduce toxicity.
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